KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Current Liabilities (2016 - 2025)

Astrazeneca has reported Total Current Liabilities over the past 11 years, most recently at $30.6 billion for Q4 2025.

  • Quarterly results put Total Current Liabilities at $30.6 billion for Q4 2025, up 9.87% from a year ago — trailing twelve months through Dec 2025 was $30.6 billion (up 9.87% YoY), and the annual figure for FY2025 was $30.6 billion, up 9.87%.
  • Total Current Liabilities for Q4 2025 was $30.6 billion at Astrazeneca, up from $27.9 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for AZN hit a ceiling of $30.6 billion in Q4 2025 and a floor of $22.6 billion in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $27.9 billion (2024), compared with a mean of $27.6 billion.
  • Biggest five-year swings in Total Current Liabilities: increased 16.37% in 2022 and later decreased 8.76% in 2024.
  • Astrazeneca's Total Current Liabilities stood at $22.6 billion in 2021, then increased by 16.37% to $26.3 billion in 2022, then rose by 16.16% to $30.5 billion in 2023, then fell by 8.76% to $27.9 billion in 2024, then rose by 9.87% to $30.6 billion in 2025.
  • The last three reported values for Total Current Liabilities were $30.6 billion (Q4 2025), $27.9 billion (Q4 2024), and $30.5 billion (Q4 2023) per Business Quant data.